Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:57 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,666 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolic Complications Clear all
Recruiting Phase 4 Interventional

DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes

NCT06445946
View directory record Official record
Conditions
Gestational Diabetes Mellitus, Pregnancy, High Risk
Interventions
Metformin, Insulin
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older · Female only
Enrollment
1,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Active, not recruiting No phase listed Observational

The REPLACE Registry for Cholbam® (Cholic Acid)

NCT03115086
View directory record Official record
Conditions
Bile Acid Synthesis Disorders
Interventions
Cholbam
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
Not listed
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2039
U.S. locations
24
States / cities
Birmingham, Alabama • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Completed No phase listed Observational

Studying Phosphorus Metabolism

NCT00066183
View directory record Official record
Conditions
Phosphorus Metabolism
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 15, 2026, 5:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation

NCT02791568
View directory record Official record
Conditions
Pregnancy, Obesity, Preeclampsia
Interventions
Ultrasound Scan, MRI Scan, Ferumoxytol
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 1Phase 2 Interventional Results available

Prevention of Macular Edema In Patients With Diabetic Retinopathy Undergoing Cataract Surgery

NCT01988246
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Aflibercept, Sham
Drug
Lead sponsor
Rishi Singh
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Nov 15, 2026, 5:57 AM EST
Terminated Phase 2 Interventional

A Phase II, Randomized, Cross-Over, Vehicle-Controlled, Double-Blind, Multicenter Study of the Safety, Pharmacodynamics, and Preliminary Efficacy of GHRP-1/AG in Subjects With ESRD on Hemodialysis

NCT00381602
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GHRP-1/AG 70 mg depot in ESRD, Placebo
Drug · Other
Lead sponsor
QLT Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
2
States / cities
New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 4, 2011 · Synced Nov 15, 2026, 5:57 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Hormonal Regulation of Postpartum Weight and Presence of Gut Peptides in Human Milk

NCT01514539
View directory record Official record
Conditions
Maternal Obesity Syndrome
Interventions
cross-sectional
Other
Lead sponsor
University of Wyoming
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Laramie, Wyoming
Source: ClinicalTrials.gov public record
Updated Jan 9, 2015 · Synced Nov 15, 2026, 5:57 AM EST
Recruiting Not applicable Interventional

PUSH-IT Continuing Enteral Feeds for Tracheostomy

NCT05906472
View directory record Official record
Conditions
Tracheostomy Complication, Critical Illness, Nutritional Deficiency
Interventions
Feeds continued, Feeds held
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Danbury, Connecticut • West Palm Beach, Florida • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Nov 15, 2026, 5:57 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)

NCT04783181
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia
Interventions
AAV BBP-631
Biological
Lead sponsor
Adrenas Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
5
States / cities
Chicago, Illinois • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Nov 15, 2026, 5:57 AM EST
Completed Not applicable Interventional

Treatment of Painful Diabetic Neuropathy With Photon Stimulation

NCT00539175
View directory record Official record
Conditions
Diabetic Neuropathy, Painful, Diabetic Neuralgia, Diabetic Polyneuropathy, Diabetic Mononeuropathy
Interventions
infrared light, infrared light; placebo
Device
Lead sponsor
East Bay Institute for Research and Education
Other
Eligibility
18 Years to 85 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Martinez, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2007 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 2 Interventional Results available

A Study to Learn How Well the Treatment Combination of Finerenone and Empagliflozin Works and How Safe it is Compared to Each Treatment Alone in Adult Participants With Long-term Kidney Disease (Chronic Kidney Disease) and Type 2 Diabetes

NCT05254002
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862 ) 10 mg, Empagliflozin, Empagliflozin Placebo, Finerenone (BAY94-8862 ) 20 mg, Finerenone Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,664 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
46
States / cities
Surprise, Arizona • Los Angeles, California • Northridge, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease

NCT00680017
View directory record Official record
Conditions
Dyslipidemia, Kidney Disease
Interventions
ABT-335 plus rosuvastatin, Rosuvastatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
102
States / cities
Birmingham, Alabama • Huntsville, Alabama • Madison, Alabama + 93 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy

NCT02065791
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Nephropathy
Interventions
Canagliflozin, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
4,401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
152
States / cities
Birmingham, Alabama • Montgomery, Alabama • Tempe, Arizona + 149 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2019 · Synced Nov 15, 2026, 5:57 AM EST
Recruiting No phase listed Observational

Drug Interaction Potential of Pro-Inflammatory Conditions

NCT07360938
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, End Stage Renal Disease, Irritable Bowel Syndrome
Interventions
None (Observational)
Other
Lead sponsor
Indiana University
Other
Eligibility
12 Years to 99 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Antibiotic Prophylaxis to Prevent Obesity-Related Induction Complications in Nulliparae at Term

NCT03801252
View directory record Official record
Conditions
Obesity, Induction of Labor Affected Fetus / Newborn
Interventions
Cefazolin, Placebo, Azithromycin
Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
15 Years to 45 Years · Female only
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 19, 2024 · Synced Nov 15, 2026, 5:57 AM EST
Terminated Phase 2 Interventional Results available

Efficacy of Aliskiren in the Treatment of Diabetic Macular Edema

NCT00768040
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Aliskiren, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
10
States / cities
Phoenix, Arizona • Los Angeles, California • Fort Myers, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2012 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

NCT01785849
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Nov 15, 2026, 5:57 AM EST
Recruiting Not applicable Interventional

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

NCT07780188
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Completed Not applicable Interventional Results available

Calcitonin for Treating X-linked Hypophosphatemia

NCT01652573
View directory record Official record
Conditions
Hypophosphatemic Rickets, X Linked Dominant
Interventions
nasal salmon calcitonin, Saline Nasal Spray Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Nov 15, 2026, 5:57 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Genetic Risk: Whether, When, and How to Tell Adolescents

NCT03421327
View directory record Official record
Conditions
Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Nov 15, 2026, 5:57 AM EST
Completed Not applicable Interventional

Time-in-range Using Continuous Glucose Monitoring Management of Gestational Diabetes Mellitus

NCT04605497
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Continuous glucose monitoring (CGM), Self-Capillary Blood Glucose Monitoring (SCBG)
Diagnostic Test
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 31, 2024 · Synced Nov 15, 2026, 5:57 AM EST
Completed Early Phase 1 Interventional Results available

Calcitriol Monotherapy for X-Linked Hypophosphatemia

NCT03748966
View directory record Official record
Conditions
X-linked Hypophosphatemia, Hypophosphatemic Rickets, Hypophosphatemic Rickets, X-Linked Dominant
Interventions
Calcitriol
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Nov 15, 2026, 5:57 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects

NCT03947970
View directory record Official record
Conditions
Hemodialysis, Healthy
Interventions
[14C] CR845
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Nov 15, 2026, 5:57 AM EST
Recruiting Not applicable Interventional

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

NCT06374277
View directory record Official record
Conditions
Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions
Med AAAction intervention
Other
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Knoxville, Tennessee • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Nov 15, 2026, 5:57 AM EST